僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Stamulumab （MYO-029） is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy （BMD）, facioscapulohumeral dystrophy （FSHD）, and limb-girdle muscular dystrophy （LGMD） research